T
1.23
-0.06 (-4.65%)
| Previous Close | 1.29 |
| Open | 1.28 |
| Volume | 33,837,779 |
| Avg. Volume (3M) | 75,157,466 |
| Market Cap | 1,381,121,664 |
| Price / Sales | 0.920 |
| Price / Book | 0.610 |
| 52 Weeks Range | |
| Earnings Date | 8 Jan 2026 |
| Profit Margin | -114.40% |
| Operating Margin (TTM) | -16.76% |
| Diluted EPS (TTM) | -1.10 |
| Quarterly Revenue Growth (YOY) | -1.40% |
| Total Debt/Equity (MRQ) | 12.73% |
| Current Ratio (MRQ) | 2.62 |
| Operating Cash Flow (TTM) | -51.09 M |
| Levered Free Cash Flow (TTM) | 26.37 M |
| Return on Assets (TTM) | -1.63% |
| Return on Equity (TTM) | -30.73% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | Tilray Brands, Inc. | Bullish | Mixed |
AIStockmoo Score
0.5
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.50 |
|
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 0.69% |
| % Held by Institutions | 10.10% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |